SUPPORTING STEMM DIVERSITY AND INCLUSION INITIATIVES FOR WOMEN IN ARTHROPLASTY, SURGERY AND ORTHOPAEDIC ONCOLOGY
With
Associate Professor Claudia Di Bella
Orthopaedic surgeon, Melbourne &
Associate Professor of Surgery
University of Melbourne
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Sydney | June 2026
Associate Professor Claudia Di Bella is an academic orthopaedic surgeon based in Melbourne, specialising in orthopaedic oncology and complex joint reconstruction. Originally trained at the world-renowned Rizzoli Orthopaedic Institute (Istituto Ortopedico Rizzoli) in Bologna, Italy, she moved to Australia in 2010 and was awarded Fellowship of the Royal Australasian College of Surgeons in 2013.
She is Associate Professor of Surgery at the University of Melbourne and leads a translational research program focused on tissue engineering and innovative solutions to improve outcomes for patients with musculoskeletal disease, in particular bone sarcomas. Her research has attracted over AUD $6 million in competitive funding, including an NHMRC–MRFF Clinical Investigator Grant, and has resulted in more than 60 peer-reviewed publications, book chapters and numerous national and international presentations. She is passionate about bridging the gap between scientific discovery and meaningful improvements in patient care.
Clinically, A/Prof Di Bella is one of Australia’s few orthopaedic oncology surgeons, managing complex bone and soft tissue tumours and performing high-volume limb salvage surgery and joint reconstruction. Her work combines surgical expertise, innovation and multidisciplinary care for patients facing life-changing diagnoses.
Beyond her clinical and academic roles, Claudia is a strong advocate for diversity, inclusion and representation in medicine. Through national and international leadership roles, including within orthopaedic surgery and sarcoma organisations, she actively mentors the next generation of surgeons and researchers, with a particular commitment to supporting women and underrepresented groups in STEMM and surgical careers.
Source: Supplied
Media access credit: Medical Technology Association of Australia (MTAA)
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
-
Metabolic health expert talks about healthy ageing
David Beard is a highly experienced Exercise Physiologist with a specialisation in metabolic health and healthy aging. He has spent over 40 years in this profession, even before exercise physiology was formally recognised as a discipline. His extensive background includes over a decade of working in aged care and a strong focus on adult health and fitness. David has authored a book on healthy aging and dedicated the last 10 to 12 years to advancing his expertise in metabolic health issues such as diabetes, weight loss, and inflammatory conditions. He is a co-owner of HFRC in Nedlands, Western Australia, where he has worked for nearly a decade.
-
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
